Considering Triple Agents in Glucose Control - Application & Safety Considerations in 2026 - Video
Overview
In this episode of The Diabetes Wellness Forum, titled "Considering Triple Agents-Application & Safety Considerations in 2026," Dr Nandita Mohan from Medical Dialogues is in conversation with Dr. Om Lakhani, Dr Om Lakhani, Consultant Endocrinologist, AB Plus Hospital, Ahmedabad and Founder of Mellitus Healthcare LLP and technochrinology.com and Dr Ganpati, Professor, Department of Endocrinology, St. Johns Medical College, Bangalore to discuss critical aspects of diabetes care in 2026.
In uncontrolled type 2 diabetes (T2D), combination therapies are often essential to achieve meaningful glycemic control. Many patients, especially younger individuals with aggressively progressing disease, require triple-drug regimens to manage high glucose levels effectively. It is therefore crucial to understand how to initiate, sequence, and monitor triple therapy safely within the T2DM care continuum. Optimizing combinations based on patient profile, comorbidities, and treatment goals can significantly improve outcomes and reduce long-term complications.
During this episode, the experts address three key clinical questions:
1. When would you consider triple glucose-lowering drug therapy combination in your T2DM patients?
2. Based on your clinical experience, what will be the edge of Empagliflozin Sitagliptin Metformin triple combination in T2DM patients among other available triple FDCs in the T2DM care landscape?
3. Based on your experience with Empagliflozin Sitagliptin, and Metformin as molecules you have used in different formulations over the years, what can be the beyond glycemic effects of this combination?
4. What is your view on the safety of the Empagliflozin Sitagliptin Metformin triple combination?
5. In which patient profiles would you consider Empagliflozin Sitagliptin Metformin FDC?
Speakers
